INTRODUCTION: This study evaluated the association between serum cystatin C and residual renal function (RRF) in peritoneal dialysis (PD) patients. METHODS: The ability of cystatin C to predict RRF was assessed. Multivariate linear regression analysis was conducted to measure the impact of particular factors on serum cystatin C levels. RESULTS: The study included 141 PD patients. Serum creatinine and cystatin C were negatively correlated with RRF (p < 0.05). Receiver operating characteristic (ROC) curves showed that serum creatinine and cystatin C could both predict RRF status (p < 0.05), but serum cystatin C had a larger area AUC than creatinine (0.893 vs. 0.757, respectively), p < 0.001). Multiple linear regression analysis revealed that RRF Kt/V and Ccr were independent factors affecting serum cystatin C levels (p < 0.001). CONCLUSION: Serum cystatin C levels were closely associated with RRF in PD patients and could reliably predict RRF status. Serum cystatin C levels were determined by RRF, not by PD.
Kidney Failure, Chronic , Peritoneal Dialysis , Humans , Creatinine , Cystatin C , Kidney/physiology , ROC Curve
Immunoglobulin Light Chains/blood , Kidney Diseases/blood , Paraproteinemias/blood , Diagnosis, Differential , Female , Humans , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Kidney Diseases/drug therapy , Kidney Function Tests , Middle Aged , Paraproteinemias/drug therapy
Catheter-Related Infections/diagnosis , Catheters, Indwelling/adverse effects , Equipment Failure , Peritoneal Dialysis, Continuous Ambulatory/adverse effects , Adult , Catheter-Related Infections/therapy , Device Removal/methods , Humans , Kidney Failure, Chronic/diagnosis , Kidney Failure, Chronic/therapy , Male , Middle Aged , Peritoneal Dialysis, Continuous Ambulatory/methods , Peritonitis/diagnosis , Peritonitis/therapy , Treatment Outcome
We investigated whether serum cystatin C predicted treatment failure and mortality in nondiabetic peritoneal dialysis (PD) patients. We studied 163 new-onset, nondiabetic PD patients between January 2010 and January 2019. Patients were followed up until death or 1 July 2019. Serum cystatin C was measured within 1 week before PD. Basic demographic and laboratory test data were collected. Patients were divided into low (<5.54 mg/L) and high (≥5.54 mg/L) serum cystatin C groups. The Kaplan-Meier method and log-rank test showed that the technical survival rate of the low cystatin C group was higher than that of the high cystatin C group. There was no difference in overall survival between the two groups. Multivariate Cox model showed that serum cystatin C was an independent risk factor for PD failure. Serum cystatin C could predict PD failure but was not associated with mortality in nondiabetic PD patients.
Cystatin C/blood , Kidney Failure, Chronic , Peritoneal Dialysis , Prognosis , China/epidemiology , Disease Progression , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Kidney Failure, Chronic/blood , Kidney Failure, Chronic/mortality , Kidney Failure, Chronic/therapy , Male , Middle Aged , Peritoneal Dialysis/methods , Peritoneal Dialysis/statistics & numerical data , Predictive Value of Tests , Proportional Hazards Models , Survival Rate
